Provided by Tiger Trade Technology Pte. Ltd.

ResMed

229.10
-0.3450-0.15%
Volume:468.90K
Turnover:107.00M
Market Cap:33.05B
PE:21.97
High:229.33
Open:226.85
Low:224.26
Close:229.44
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:0.54
T/O Rate:0.33%
Dividend:2.46
Dividend Rate:1.07%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:5.02
PE(LYR):21.97

Loading ...

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 08

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 07

ResMed Adjusts CDI and Share Counts Amid Cross-Market Transfers and Buybacks

TIPRANKS
·
Sep 07

Statement of CDIs on Issue - RMD-RMD.N

Reuters
·
Sep 07

Resmed Inc.-Statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Sep 07

Statement of Changes in Beneficial Ownership-RMD.N

Reuters
·
Sep 07

ResMed Director Peter C. Farrell Disposes of 970 Common Shares Worth $227,688.10

Reuters
·
Sep 04

Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating

MT Newswires Live
·
Sep 03

Is ResMed (RMD) Below Fair Value On The MatrixCare Sale?

Simply Wall St.
·
Sep 02

Resmed Inc.-Accelerated Share Repurchase Agreement Announcement

THOMSON REUTERS
·
Sep 02

ResMed Launches $450 Million Accelerated Share Buyback With Citibank

MT Newswires Live
·
Sep 02

ResMed to Buy Back $450M in Stock Under Accelerated Share Repurchase Agreement

Dow Jones
·
Sep 02

ResMed Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
Sep 02

Resmed - to Fund Share Repurchase with Matrixcare Sale Proceeds and Cash on Hand - SEC Filing

THOMSON REUTERS
·
Sep 02

Resmed - Enters Accelerated Share Repurchase Agreement to Repurchase $450 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
Sep 02

Resmed - Final Settlement of Asr Agreement Scheduled for December 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

Resmed Inc Stock (RMD) Moved Down by 3.25% on Sep 1: Facts Behind the Movement

TradingKey
·
Sep 02

ResMed completes divestment of MatrixCare to Frazier Healthcare Partners

TIPRANKS
·
Sep 01

ResMed Price Target Raised to $267.00/Share from $255.00 by Keybanc

Dow Jones
·
Aug 31

KeyBanc Adjusts Price Target on ResMed to $267 From $255, Keeps Overweight Rating

MT Newswires Live
·
Aug 31